Associated Papers
Genetic polymorphisms and platinum-induced hematological toxicity: a systematic review.
Zheng Y et al.
Frontiers in Pharmacology, 2024
Association between Single Nucleotide Polymorphisms and Glioma Risk: A Systematic Literature Review.
Tavares CB et al.
Cancer Investigation, 2020
Study of the Relationship between ERCC1 Polymorphisms and Response to Platinum-based Chemotherapy in Iranian Patients with Colorectal and Gastric Cancers.
Abyarghamsari M et al.
Iranian Journal of Pharmaceutical Research : Ijpr, 2019
Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.
Beheshti F et al.
Journal of Cellular Physiology, 2018
Genetic prediction of long-term survival after neoadjuvant chemoradiation in locally advanced esophageal cancer.
Gusella M et al.
The Pharmacogenomics Journal, 2017
Investigating the Frequency of the ERCC1 Gene C8092A Polymorphism in Iranian Patients with Advanced Gastric Cancer Receiving Platinum-based Chemotherapy.
Mokmeli S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2016
Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015
Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
Lee MS et al.
Lung Cancer (amsterdam, Netherlands), 2015
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.
Zhang S et al.
The Journal of Molecular Diagnostics : Jmd, 2015
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Tiseo M et al.
British Journal of Cancer, 2013
ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes.
Lu X et al.
Plos One, 2013
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
Yin M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Huang MY et al.
Pharmacogenetics and Genomics, 2011
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
Bradbury PA et al.
Pharmacogenetics and Genomics, 2009
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Lai JI et al.
Cancer Science, 2009
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
Pacetti P et al.
Anticancer Research, 2009
Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E et al.
British Journal of Cancer, 2006
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005